Hearing loss: an overlooked, modifiable dementia risk factor
Hearing loss is one of the larger modifiable contributors to dementia risk, and one of the most fixable. What the evidence says, including the ACHIEVE trial.
By the OutliveAPOE4 editorial team. How we research & source.
When people list things that protect the brain, hearing rarely comes up. It should. In major analyses of modifiable dementia risk, hearing loss stands out as one of the larger contributors across the population, and unlike most risk factors, it’s something that can often be directly addressed.
Why would hearing affect the brain?
Researchers don’t have a single airtight answer, but several explanations are plausible and probably overlap:
- Cognitive load. When sound is degraded, the brain burns extra effort just to decode speech, effort that’s pulled away from memory and thinking.
- Reduced stimulation. Less rich auditory input may, over years, contribute to changes in how the brain maintains itself.
- Social withdrawal. Struggling to follow conversations nudges people toward isolation, itself a recognized risk factor.
An association isn’t the same as proof that treating hearing prevents dementia, which is what makes the trial evidence interesting.
What the ACHIEVE trial actually found
ACHIEVE, published in The Lancet in 2023, was a randomized trial testing whether a hearing intervention (hearing aids and audiology support) slowed cognitive decline in adults aged 70 to 84 with untreated hearing loss. The result needs to be read carefully:
- In the primary analysis combining the whole study group, the intervention showed no significant effect on three-year cognitive change (the two groups were essentially identical, p=0.96).
- The cohort was drawn from two groups: older participants from a long-running cardiovascular study (ARIC), who had more risk factors and lower baseline scores, and healthier community volunteers. A prespecified analysis found the intervention’s effect differed significantly between these two groups, with the benefit concentrated in the higher-risk ARIC participants.
So the headline finding was null, but the prespecified subgroup signal in higher-risk older adults, who plausibly include many APOE4 carriers, is encouraging. It is still a fair distance from “hearing aids prevent dementia for everyone,” and researchers are continuing to untangle it.
The practical takeaway
Even setting dementia aside, treating hearing loss improves communication, mood, and quality of life, so the downside of acting is low and the potential upside is real.
- Get your hearing checked, especially from midlife on, and don’t shrug off “everyone mumbles these days.”
- Take hearing loss seriously when found. Modern hearing aids are far better and less obtrusive than their reputation.
- Protect the hearing you have from loud noise exposure.
It’s a rare combination: a brain-health lever that’s measurable, treatable, and worth pulling for everyday reasons regardless of how the long-term dementia data ultimately shakes out.
Sources & further reading
Related deep dives
- APOE4 and Alzheimer’s risk: what the numbers actually mean Relative risk, absolute risk, and age of onset: how to read the scary statistics about APOE4 and Alzheimer’s without losing perspective.
- How APOE4 affects the brain APOE4 influences how the brain clears amyloid, handles lipids, and manages inflammation. A plain-language tour of the leading mechanisms and what’s still uncertain.
- APOE4, women, and sex differences in risk Evidence suggests APOE4 may carry a different risk profile for women than men, especially at certain ages. Here’s what the research shows, and its limits.